Unicycive Therapeutics annual ebitda
2020
2021
2022
2023
2024
2025
Unicycive Therapeutics EBITDA Growth & History (UNCY)
Unicycive Therapeutics's calculated EBITDA was −$29.5M for fiscal 2025.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$29.5M | $2.6M | — |
| 2024 | 2024-12-31 | −$32.1M | −$11.3M | — |
| 2023 | 2023-12-31 | −$20.8M | −$3.1M | — |
| 2022 | 2022-12-31 | −$17.6M | −$9.1M | — |
| 2021 | 2021-12-31 | −$8.5M | −$6.6M | — |
| 2020 | 2020-12-31 | −$2.0M | — | — |
Unicycive Therapeutics quarterly ebitda
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$10.1M | −$3.2M | — |
| Q1 2026 | 2026-03-31 | −$8.4M | −$448,000 | — |
| Q4 2025 | 2025-12-31 | −$7.2M | $2.0M | — |
| Q3 2025 | 2025-09-30 | −$7.3M | −$1.1M | — |
| Q2 2025 | 2025-06-30 | −$7.0M | $444,000 | — |
| Q1 2025 | 2025-03-31 | −$8.0M | $1.2M | — |
| Q4 2024 | 2024-12-31 | −$9.3M | −$2.9M | — |
| Q3 2024 | 2024-09-30 | −$6.2M | −$309,000 | — |
| Q2 2024 | 2024-06-30 | −$7.4M | −$3.1M | — |
| Q1 2024 | 2024-03-31 | −$9.2M | −$5.0M | — |
| Q4 2023 | 2023-12-31 | −$6.3M | −$1.1M | — |
| Q3 2023 | 2023-09-30 | −$5.9M | −$383,000 | — |
| Q2 2023 | 2023-06-30 | −$4.3M | −$686,000 | — |
| Q1 2023 | 2023-03-31 | −$4.2M | −$933,000 | — |
| Q4 2022 | 2022-12-31 | −$5.2M | — | — |
| Q3 2022 | 2022-09-30 | −$5.6M | — | — |
| Q2 2022 | 2022-06-30 | −$3.6M | — | — |
| Q1 2022 | 2022-03-31 | −$3.3M | — | — |
Unicycive Therapeutics ebitda trends
Over the last five fiscal years, Unicycive Therapeutics's ebitda decreased from −$2.0M to −$29.5M, a change of −$27.5M. The latest reported quarter, Q2 2026, shows −$10.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗Community posts
Unicycive resubmits kidney-drug application with new manufacturer data
Unicycive ($UNCY) resubmitted its US application for oxylanthanum carbonate, an investigational oral phosphate binder for dialysis patients with chronic kidney disease. The package includes manufacturing and quality data from a new third-pa ...
